In 1367 women with advanced BRCA non-mutated ovarian cancer, pembrolizumab-chemotherapy then pembrolizumab-olaparib maintenance improved progression-free survival vs chemotherapy (ITT HR 0·68 interim, 0·71 final); pembrolizumab alone did not (CPS≥10 HR 0·95).
RCTn = 1,367
Vergote et al. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial